In older adults taking aspirin, the risk of bleeding is higher if they are on 100 mg instead of 50 mg, have had bleeding before, have high cholesterol, or are taking other blood-thinning medications.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of RCTs would determine whether reducing aspirin dose from 100 mg to 50 mg consistently reduces bleeding risk across subgroups defined by prior hemorrhage, dyslipidemia, or polypharmacy.
A systematic review and meta-analysis of individual participant data from RCTs comparing 50 mg and 100 mg aspirin in older adults, stratifying bleeding outcomes by prior hemorrhage, LDL-C levels, and concomitant anticoagulant use, with interaction tests to assess effect modification.
A randomized trial would determine whether lowering aspirin dose from 100 mg to 50 mg reduces bleeding risk specifically in patients with prior hemorrhage, dyslipidemia, or on anticoagulants.
A multicenter RCT of 2,000 older adults with prior hemorrhage or dyslipidemia and on anticoagulants or other antiplatelets, randomized 1:1 to 50 mg or 100 mg aspirin for 3 years, with primary endpoint of any bleeding (BARC ≥1), and pre-specified subgroup analysis by baseline risk factors.
A prospective cohort with detailed longitudinal data could confirm whether these factors remain predictive of bleeding over time and whether their effects are additive.
A prospective cohort of 8,000 older adults on aspirin, with quarterly assessments of aspirin dose, lipid levels, bleeding history, and concomitant medications, and annual bleeding event adjudication over 5 years, using time-varying covariate models.
A case-control study could assess whether prior exposure to these risk factors is more common among those who experienced bleeding than among matched controls.
A nested case-control study within the LAPIS cohort comparing 250 patients with major bleeding to 500 matched controls, assessing prior aspirin dose, lipid levels, bleeding history, and concomitant medication use prior to event, with exposure data collected prospectively and blinded to outcome.
A cross-sectional survey could estimate the prevalence of these risk factors among older adults currently experiencing bleeding symptoms while on aspirin.
A national survey of 10,000 older adults on aspirin, collecting self-reported bleeding symptoms, current aspirin dose, lipid levels, and concomitant medications via structured interviews and pharmacy records, with validation of aspirin use via blood salicylate levels in a subsample.